FSD Pharma Inc. (NASDAQ:HUGE – Get Rating) saw a large increase in short interest during the month of July. As of July 31st, there was short interest totalling 492,200 shares, an increase of 15.0% from the July 15th total of 428,000 shares. Based on an average trading volume of 69,300 shares, the short-interest ratio is currently 7.1 days. Approximately 2.8% of the company's stock are sold short.

FSD Pharma Stock Up 4.2 %

NASDAQ:HUGE opened at $1.00 on Friday. FSD Pharma has a 12 month low of $0.69 and a 12 month high of $1.94. The company has a 50 day simple moving average of $0.88 and a two-hundred day simple moving average of $0.91.

FSD Pharma (NASDAQ:HUGE – Get Rating) last announced its quarterly earnings results on Friday, May 13th. The company reported ($0.14) EPS for the quarter.

About FSD Pharma

FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

Featured Articles

• Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
• 2 Important Retail Stock Battles to Watch
• MarketBeat: Week in Review 8/8 – 8/12
• What Is WallStreetBets and What Stocks Are They Targeting?
• Institutions And Analysts Propel Jack In The Box Higher
• Can You Guess Which EV Stock Is Beating Tesla ?

Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.